Reese D M
Department of Medicine, UCSF Comprehensive Cancer Center, University of California San Francisco, USA.
Hematol Oncol Clin North Am. 2001 Jun;15(3):547-57. doi: 10.1016/s0889-8588(05)70231-8.
Given the poor results with currently available therapies, it is imperative that new treatments be developed for patients with advanced prostate cancer. The next generation of therapies will include many novel biologic agents targeted at molecular defects in the cancer cell. Investigating the efficacy and safety of these compounds and evaluating their utility in combination with traditional therapies such as chemotherapy or radiotherapy are major goals of prostate cancer clinical research for the next decade.
